JP2004517853A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004517853A5 JP2004517853A5 JP2002554050A JP2002554050A JP2004517853A5 JP 2004517853 A5 JP2004517853 A5 JP 2004517853A5 JP 2002554050 A JP2002554050 A JP 2002554050A JP 2002554050 A JP2002554050 A JP 2002554050A JP 2004517853 A5 JP2004517853 A5 JP 2004517853A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- methyl
- methylsulfonyl
- pharmaceutical composition
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 21
- 229940111134 coxibs Drugs 0.000 claims 17
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 17
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 claims 13
- 239000002464 receptor antagonist Substances 0.000 claims 13
- 229940044551 receptor antagonist Drugs 0.000 claims 13
- -1 4- (methylsulfonyl) phenyl Chemical group 0.000 claims 8
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 7
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- FZYAFLPJDVKKQI-KRWDZBQOSA-N (5s)-5-ethyl-5-methyl-4-(4-methylsulfonylphenyl)-3-propan-2-yloxyfuran-2-one Chemical compound CC[C@]1(C)OC(=O)C(OC(C)C)=C1C1=CC=C(S(C)(=O)=O)C=C1 FZYAFLPJDVKKQI-KRWDZBQOSA-N 0.000 claims 5
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims 5
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 claims 5
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 5
- YICWVYSPJDTUBI-IBGZPJMESA-N (2s)-2-pyrimidin-5-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1([C@H](CCCCCCCC=2N=C3NCCCC3=CC=2)C(=O)O)=CN=CN=C1 YICWVYSPJDTUBI-IBGZPJMESA-N 0.000 claims 4
- 208000002679 Alveolar Bone Loss Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 208000028169 periodontal disease Diseases 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- SQHBOFQKSIBJAM-FQEVSTJZSA-N (2s)-2-(2-methylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1[C@@H](C(O)=O)CCCCCCCC1=CC=C(CCCN2)C2=N1 SQHBOFQKSIBJAM-FQEVSTJZSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- SKSCYVSLPPEPOB-IBGZPJMESA-N (2S)-2-(2-methoxypyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound COc1ncc(cn1)[C@H](CCCCCCCc1ccc2CCCNc2n1)C(O)=O SKSCYVSLPPEPOB-IBGZPJMESA-N 0.000 claims 1
- ZFRPDDKGHCDPNI-OAQYLSRUSA-N (2s)-2-(2,3-dihydro-1-benzofuran-6-yl)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propanoic acid Chemical compound C1=C2CCOC2=CC([C@@H](CN2C(N(CCCC=3N=C4NCCCC4=CC=3)CC2)=O)C(=O)O)=C1 ZFRPDDKGHCDPNI-OAQYLSRUSA-N 0.000 claims 1
- WFGDRRYHDBVFAY-HXUWFJFHSA-N (2s)-2-(4-ethoxy-3-fluorophenyl)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propanoic acid Chemical compound C1=C(F)C(OCC)=CC=C1[C@H](C(O)=O)CN1C(=O)N(CCCC=2N=C3NCCCC3=CC=2)CC1 WFGDRRYHDBVFAY-HXUWFJFHSA-N 0.000 claims 1
- COHQTPRYVPREMW-HXUWFJFHSA-N (2s)-2-(6-ethoxypyridin-3-yl)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propanoic acid Chemical compound C1=NC(OCC)=CC=C1[C@H](C(O)=O)CN1C(=O)N(CCCC=2N=C3NCCCC3=CC=2)CC1 COHQTPRYVPREMW-HXUWFJFHSA-N 0.000 claims 1
- VMECIHUPKIKOEW-LJQANCHMSA-N (2s)-2-(6-methoxypyridin-3-yl)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propanoic acid Chemical compound C1=NC(OC)=CC=C1[C@H](C(O)=O)CN1C(=O)N(CCCC=2N=C3NCCCC3=CC=2)CC1 VMECIHUPKIKOEW-LJQANCHMSA-N 0.000 claims 1
- YHEYEOGCIDCGAJ-QHCPKHFHSA-N (2s)-2-quinolin-3-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=CC=CC2=CC([C@H](CCCCCCCC=3N=C4NCCCC4=CC=3)C(=O)O)=CN=C21 YHEYEOGCIDCGAJ-QHCPKHFHSA-N 0.000 claims 1
- IEYOLYRZESWODM-JOCHJYFZSA-N (2s)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]-2-quinolin-3-ylpropanoic acid Chemical compound C1=CC=CC2=CC([C@@H](CN3C(N(CCCC=4N=C5NCCCC5=CC=4)CC3)=O)C(=O)O)=CN=C21 IEYOLYRZESWODM-JOCHJYFZSA-N 0.000 claims 1
- XJXCVNTUWJYXTM-OAQYLSRUSA-N (5r)-3-(3-chloro-4-methoxyphenoxy)-5-ethyl-5-methyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound O([C@](C=1C=2C=CC(=CC=2)S(C)(=O)=O)(C)CC)C(=O)C=1OC1=CC=C(OC)C(Cl)=C1 XJXCVNTUWJYXTM-OAQYLSRUSA-N 0.000 claims 1
- XCNHDBDVIVAJHX-UHFFFAOYSA-N 3-(5-bromopyridin-2-yl)oxy-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OC1=CC=C(Br)C=N1 XCNHDBDVIVAJHX-UHFFFAOYSA-N 0.000 claims 1
- HGFOOLONGOBCMP-UHFFFAOYSA-N 3-(6-methoxypyridin-3-yl)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propanoic acid Chemical compound C1=NC(OC)=CC=C1C(CC(O)=O)N1C(=O)N(CCCC=2N=C3NCCCC3=CC=2)CC1 HGFOOLONGOBCMP-UHFFFAOYSA-N 0.000 claims 1
- INRQTVDUZFESAO-UHFFFAOYSA-N 4-(3,4-difluorophenyl)-3-(4-methylsulfonylphenyl)-2h-furan-5-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=C(F)C(F)=CC=2)C(=O)OC1 INRQTVDUZFESAO-UHFFFAOYSA-N 0.000 claims 1
- KZNGNTKISMAXAG-UHFFFAOYSA-N 4-(3-fluorophenyl)-3-(4-methylsulfonylphenyl)-2h-furan-5-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=C(F)C=CC=2)C(=O)OC1 KZNGNTKISMAXAG-UHFFFAOYSA-N 0.000 claims 1
- LQDZIMSKYUVVHN-UHFFFAOYSA-N 4-[4-(3,4-dichlorophenyl)-5-oxo-2h-furan-3-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=C(Cl)C(Cl)=CC=2)C(=O)OC1 LQDZIMSKYUVVHN-UHFFFAOYSA-N 0.000 claims 1
- KEHWUUBPFIVOBI-UHFFFAOYSA-N 4-[4-(3-chloro-4-methoxyphenyl)-5-oxo-2h-furan-3-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(OC)=CC=C1C1=C(C=2C=CC(=CC=2)S(N)(=O)=O)COC1=O KEHWUUBPFIVOBI-UHFFFAOYSA-N 0.000 claims 1
- ONJHHYBWKLDIFI-UHFFFAOYSA-N 5,5-dimethyl-4-(4-methylsulfonylphenyl)-3-propan-2-yloxyfuran-2-one Chemical compound CC1(C)OC(=O)C(OC(C)C)=C1C1=CC=C(S(C)(=O)=O)C=C1 ONJHHYBWKLDIFI-UHFFFAOYSA-N 0.000 claims 1
- WRQFOMMHNDHSPD-UHFFFAOYSA-N 5-chloro-2-(6-ethylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine Chemical compound C1=NC(CC)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 WRQFOMMHNDHSPD-UHFFFAOYSA-N 0.000 claims 1
- CUVUXNULRBGYON-UHFFFAOYSA-N L787257 Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(Cl)=CN=C1C1=CC=CN=C1 CUVUXNULRBGYON-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003239 periodontal effect Effects 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25944101P | 2001-01-03 | 2001-01-03 | |
| PCT/US2001/049638 WO2002053099A2 (en) | 2001-01-03 | 2001-12-28 | Methods and compositions for treating periodontal disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004517853A JP2004517853A (ja) | 2004-06-17 |
| JP2004517853A5 true JP2004517853A5 (de) | 2005-12-22 |
Family
ID=22984959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002554050A Withdrawn JP2004517853A (ja) | 2001-01-03 | 2001-12-28 | 歯周病の治療方法及び治療用組成物 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1349548A4 (de) |
| JP (1) | JP2004517853A (de) |
| AU (1) | AU2002246757B2 (de) |
| CA (1) | CA2432504A1 (de) |
| WO (1) | WO2002053099A2 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| EP4249471A3 (de) | 2013-09-24 | 2023-10-18 | FUJIFILM Corporation | Pharmazeutische zusammensetzung von stickstoffhaltige verbindung oder salz davon oder metallkomplex davon |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5190981A (en) * | 1989-08-17 | 1993-03-02 | Sepracor Inc. | Formulation containing S(+) enantiomer of flurbiprofen or ketoprofen and method of use for oral administration for prevention and treatment of bone loss associated with periodontal disease |
| US20020028798A1 (en) * | 1995-12-12 | 2002-03-07 | Omeros Medical Systems | Irrigation solution and method for inhibition of pain and inflammation |
| WO1999031099A1 (en) * | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6136804A (en) * | 1998-03-13 | 2000-10-24 | Merck & Co., Inc. | Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions |
| EP1100506A4 (de) * | 1998-07-29 | 2002-06-26 | Merck & Co Inc | Integrin rezeptor antagonisten |
| HUP0302468A2 (hu) * | 1999-06-02 | 2003-11-28 | Merck & Co., Inc. | Alfa V integrin receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények |
-
2001
- 2001-12-28 JP JP2002554050A patent/JP2004517853A/ja not_active Withdrawn
- 2001-12-28 CA CA002432504A patent/CA2432504A1/en not_active Abandoned
- 2001-12-28 WO PCT/US2001/049638 patent/WO2002053099A2/en active IP Right Grant
- 2001-12-28 EP EP01994350A patent/EP1349548A4/de not_active Ceased
- 2001-12-28 AU AU2002246757A patent/AU2002246757B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014372166B2 (en) | Pharmaceutical combinations | |
| RU2361860C2 (ru) | Новые замещенные 3-сера-индолы | |
| US20140011798A1 (en) | Imidazopyrrolidinone compounds | |
| JP2018511626A5 (de) | ||
| CA2345641A1 (en) | A method for treating inflammatory diseases by administering a thrombin inhibitor | |
| JP2007519649A5 (de) | ||
| JP2006503866A (ja) | 癌を処置するための相乗的な方法および組成物 | |
| JP2015517566A5 (de) | ||
| IL205501A (en) | Preparation of preparations for the treatment of arthritis | |
| JP2013531070A5 (de) | ||
| JP2009501775A5 (de) | ||
| JP2016531139A (ja) | 過剰増殖性疾患の治療のためのｍｅｋ阻害剤とｅｒｋ阻害剤の組合せの使用 | |
| RU2003112610A (ru) | Производные пиразола для лечения вирксных заболеваний | |
| RU2003103780A (ru) | Соединения фенилпиридазина и содержащие их лекарственные средства | |
| JP2005520797A5 (de) | ||
| AU2713400A (en) | Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia | |
| WO2005074930A1 (en) | Pharmaceutical combinations of (s) -pantoprazole with nsaid or corticosteroids | |
| JP2004517853A5 (de) | ||
| US20020016342A1 (en) | Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor | |
| NL1024816C2 (nl) | Met kleefstof bekleed vel voor dermale aflevering van een selectieve cyclooxygenase-2-remmer. | |
| JP2004524279A5 (de) | ||
| JP2006516626A5 (de) | ||
| JP2011524362A5 (de) | ||
| EP1251839A2 (de) | Verwendung von cox-2 inhibitoren zur behandlung von darmverstopfung | |
| US20050004199A1 (en) | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |